Increasing BDNF levels over 3 months in patients with MS treated with glatiramer acetate, afterwards levels remained stable but significantly higher compared to controlsDecreased IFN-g, IL4, IL5, IL10 in patients treated with glatiramer acetateNo effect of IFN-β1a/minimal decrease of BDNF levels under immunoglobulin treatmentIncrease of IL10 in patients treated with IFN-β1a. This evidence concerns the gene BDNF and myeloid sarcoma.